PRL and neoplasm: DAs, especially cabergoline, are the first-choice treatment for patients with prolactin (PRL)-secreting PitNETs, since they are effective in inducing prolactin normalization and in reducing tumor size, but about 10% of patients are resistant to the treatment [1].